Chimeric Therapeutics ASX: CHM

CEO Dr. Rebecca McQualter will present at 10:00am AEDT on 25 March 2026 at the @NWRcomms Healthcare Conference. 📌 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted live or in advance via matt@nwrcommunications.com.au. More info: nwrcommunications.com/events/healthc… $CHM

Letter to Shareholders: March 2026 View the full $CHM Announcement here: app.sharelinktechnologies.com/announcement-p…

In case you missed it: @Chimeric was featured in @StockheadAU's #Health & #Biotech Investor Guide 2026. The segment highlights our lead CAR-T therapy $CHM CDH17, early patient outcomes from our US Phase 1/2 trial, and our focus on tackling solid tumours. Watch the feature below.

March is Colorectal Cancer Awareness Month. $CHM CDH17 is being studied in advanced colorectal cancer and other gastrointestinal cancers in our Phase 1/2 trial. Our focus is progressing CHM CDH17 through clinical development advancing new potential treatment options for patients.

We’ve received $1,785,000 from Radium Capital under a funding facility secured against our anticipated FY26 Research and Development Tax Incentive. Funds will support our clinical trial pipeline and general working capital. app.sharelinktechnologies.com/announcement-p… $CHM #CellTherapy

We've released our Half-year Report ended 31 December 2025. View the full $CHM report here: app.sharelinktechnologies.com/announcement-p…

We’ve entered into an arrangement to return CHM CLTX to City of Hope. Following a strategic review, the Board determined this represents a disciplined capital management decision aligned with our focus on advancing $CHM CDH17. app.sharelinktechnologies.com/announcement-p…

We’re featured in the latest @StockheadAU Investor Guide, highlighting the progress of our US clinical programs and the patient impact driving our work. Read more in the latest Stockhead Investor Guide: stockhead.com.au/investor-guide… $CHM

Our CEO, Dr Rebecca McQualter on stage at Life Science Investor Day in Sydney, hosted by @MTPConnect_AUS and @wholesaleinvest. A great opportunity to share progress on $CHM CDH17 and connect with investors across the life sciences community.

We’ve appointed biotechnology executive and cell therapy specialist Dr Bradley Glover as Non-Exec Director & Chair as part of our Board refresh. Phillip Hains retires as CFO and Joint Company Secretary, & we’ve appointed Aaron Laurita as CFO. $CHM More: app.sharelinktechnologies.com/announcement-p…

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals | $CHM Media coverage by Biotech Dispatch. biotechdispatch.com.au/news/chimeric-… @AusBiotech

We’ve advanced to Dose Level 3 (450m cells) in our $CHM CDH17 Phase 1/2 trial, with no safety or off target effects observed at Dose Levels 1 & 2. Dose Level 2 patients continue to experience disease control with anti-tumour activity. app.sharelinktechnologies.com/announcement-p…

Today is International Women and Girls in #Science Day. At @Chimeric, women are part of the teams advancing our clinical-stage cell therapy programs. Diverse perspectives strengthen how we think, lead and develop treatments for patients with cancer.

Today is #WorldCancerDay - a reminder that behind every statistic is a person and a family. At @Chimeric, we’re advancing next-generation cell therapies, including $CHM CDH17 for gastrointestinal and neuroendocrine cancers, focused on improving outcomes for patients.

Our CEO Dr Rebecca McQualter will present at Emergence 2026: Life Science Day on 18 Feb at the Four Seasons Hotel, Sydney (3:50pm, 8-minute pitch). Rebecca will speak to our progress advancing next-generation CAR T therapies to improve outcomes for patients with cancer. $CHM

Colorectal cancer is the leading cause of #cancer death in under 50 in the US. At @Chimeric, our lead program $CHM CDH17 targets GI cancers, including colorectal cancer. Our Phase 1/2 trial is progressing through dose escalation with encouraging safety & disease control signals.

Our Quarterly Activities Report for the period ending 31 December 2025 has been released. View the full $CHM Report here:  app.sharelinktechnologies.com/announcement-p… #CellTherapy #Oncology #CART #Biotech #CancerResearch

At #JPM25, CEO Dr Rebecca McQualter is progressing discussions on $CHM CDH17, our lead CAR-T program for colorectal, gastric and GI neuroendocrine cancers. Dose Level 2 is complete, and the trial is moving to final Dose Level 3, the final cohort in the dose-escalation phase.

As the year comes to a close, we thank our patients, families, clinicians, collaborators & shareholders who supported @Chimeric in 2025. This year delivered important clinical progress & regulatory milestones across our programs. We wish everyone a safe & restful holiday season.

We’ve secured $8.4m via a $4.4m Placement & $4.0m Convertible Note to fully fund the $CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, enabling continued execution following encouraging safety & disease control signals. app.sharelinktechnologies.com/announcement-p…